Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and effectiveness of a new drug called lenalidomide
(Revlimid) for treating patients with chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL) who relapsed after their initial treatment.
Patients 21 years of age and older with CLL or SLL who have previously received standard
treatment may be eligible for this study.
Participants take lenalidomide capsules once a day for 21 days, followed by 21 days off the
drug. This constitutes one treatment cycle. Treatment continues for four cycles as long as
the medicine is tolerated. After four cycles, patients who respond completely continue
treatment for another two cycles; patients who respond partially continue treatment for
another four cycles; and patients who do not respond stop treatment but continue to be
followed for safety.
...